Recent Updates
Recently added Catalysts
OCS Positive Sentiment

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Thursday, October 8, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Oculis has published a notification regarding the vesting and settlement of Restricted Stock Units (RSUs) for a member of its Executive Committee and Board of Directors. This transaction, involving Riad Sherif, took place on October 5, 2026. The notification underscores the company's commitment to transparency in its managerial activities.

Market Sentiment Analysis

POSITIVE FACTORS

  • Notification indicates transparency in managerial transactions.
  • Vesting of RSUs reflects positive company performance.
  • Engagement of executive committee shows commitment to shareholders.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+32%
120-day peak, hindsight
Typical move
2.2%
average across 3 past catalysts
Lead asset
Privosegtor
Phase 3 · Optic Neuritis

Full Press Release Details

ZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a member of the Company’s Executive Committee and Board of Directors. Attachment Notification of managers' transaction - Riad Sherif - 5 October 2026 RSU

Frequently Asked Questions

What is the notification about?

The notification relates to the vesting and settlement of RSUs for an executive.

Who is involved in the transaction?

The transaction involves Riad Sherif, a member of the Executive Committee.

When did the transaction occur?

The transaction took place on October 5, 2026.

What does RSU stand for?

RSU stands for Restricted Stock Units.

ShareAdd on Google
Tags: OCS Oculis RSUs executive committee Riad Sherif transparency
Last updated: Oct 8, 2026

Biotech snapshot

Lead asset
PrivosegtorPhase 3
Optic Neuritis →

Catalyst track record

+32%
best trade around OCS's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for OCS.

See every catalyst's timing & PoA →